Добро пожаловать
Зарегистрировать аккаунт
Войдите, используя email
Зарегистрируйтесь с помощью email
Проверь свои входящие
Immusoft
About
Immusoft, a biotechnology company, commercializes technologies that program the human immune system by modifying the DNA in related cells.
- 11 - 50
Details
- Last Funding Type
- Grant
- Last Funding Money Raised
- $467K
- Industries
- Biotechnology,Life Science,Therapeutics
- Founded date
- Jan 1, 2009
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Immusoft is a biotechnology company that is commercializing technology to program the human immune system by modifying the DNA in immune cells. The core components of Immusoft’s Immune System Programming (ISP) technology was developed in the Baltimore Lab at the California Institute of Technology (Caltech) and exclusively licensed by Immusoft.The technology instructs a patient’s cells to produce gene-encoded medicines (biologics). Cells that are reprogrammed using ISP become miniature drug factories that are expected to survive in patients for many years.It was founded in 2009 and is headquartered in Seattle, Washington.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Sep 25, 2020 | Grant | $467K | 1 |
National Institutes of Health
|
— | Detail |
| Nov 7, 2016 | Series A | $2.70M | 1 |
|
— | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
National Institutes of Health
|
Yes | Grant |
|
|
Yes | Series A |
